Literature DB >> 25818427

Scaffold composition affects cytoskeleton organization, cell-matrix interaction and the cellular fate of human mesenchymal stem cells upon chondrogenic differentiation.

Yuk Yin Li1, Tze Hang Choy1, Fu Chak Ho1, Pui Barbara Chan2.   

Abstract

The stem cell niche, or microenvironment, consists of soluble, matrix, cell and mechanical factors that together determine the cellular fates and/or differentiation patterns of stem cells. Collagen and glycosaminoglycans (GAGs) are important scaffolding materials that can mimic the natural matrix niche. Here, we hypothesize that imposing changes in the scaffold composition or, more specifically, incorporating GAGs into the collagen meshwork, will affect the morphology, cytoskeletal organization and integrin expression profiles, and hence the fate of human mesenchymal stem cells (MSCs) upon the induction of differentiation. Using chondrogenesis as an example, we microencapsulated MSCs in three scaffold systems that had varying matrix compositions: collagen alone (C), aminated collagen (AC) and aminated collagen with GAGs (ACG). We then induced the MSCs to differentiate toward a chondrogenic lineage, after which, we characterized the cell viability and morphology, as well as the level of cytoskeletal organization and the integrin expression profile. We also studied the fate of the MSCs by evaluating the major chondrogenic markers at both the gene and protein level. In C, MSC chondrogenesis was successfully induced and MSCs that spread in the scaffolds had a clear actin cytoskeleton; they expressed integrin α2β1, α5 and αv; promoted sox9 nuclear localization transcription activation; and upregulated the expression of chondrogenic matrix markers. In AC, MSC chondrogenesis was completely inhibited but the scaffold still supported cell survival. The MSCs did not spread and they had no actin cytoskeleton; did not express integrin α2 or αv; they failed to differentiate into chondrogenic lineage cells even on chemical induction; and there was little colocalization or functional interaction between integrin α5 and fibronectin. In ACG, although the MSCs did not express integrin α2, they did express integrin αv and there was strong co-localization and hence functional binding between αv and fibronectin. In addition, vimentin was the dominant cytoskeletal protein in these cells, and the chondrogenic marker genes were expressed but at a much lower level than in the MSCs encapsulated in C alone. This work suggests the importance of controlling the matrix composition as a strategy to manipulate cell-matrix interactions (through changes in the integrin expression profile and cytoskeleton organization), and hence stem cell fates.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cellular fates; Cell–matrix interaction; Chondrogenesis; Collagen; Glycosaminoglycans; Mesenchymal stem cell

Mesh:

Substances:

Year:  2015        PMID: 25818427     DOI: 10.1016/j.biomaterials.2015.02.037

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  13 in total

1.  Curved microstructures promote osteogenesis of mesenchymal stem cells via the RhoA/ROCK pathway.

Authors:  Qi Zhang; Shiyu Lin; Tao Zhang; Taoran Tian; Quanquan Ma; Xueping Xie; Changyue Xue; Yunfeng Lin; Bofeng Zhu; Xiaoxiao Cai
Journal:  Cell Prolif       Date:  2017-08       Impact factor: 6.831

2.  The potential of chondrogenic pre-differentiation of adipose-derived mesenchymal stem cells for regeneration in harsh nucleus pulposus microenvironment.

Authors:  Jingkai Wang; Yiqing Tao; Xiaopeng Zhou; Hao Li; Chengzhen Liang; Fangcai Li; Qi-Xin Chen
Journal:  Exp Biol Med (Maywood)       Date:  2016-08-19

3.  Protease inhibitors enhance extracellular collagen fibril deposition in human mesenchymal stem cells.

Authors:  Sejin Han; Yuk Yin Li; Barbara Pui Chan
Journal:  Stem Cell Res Ther       Date:  2015-10-15       Impact factor: 6.832

4.  Mesenchymal Stem Cells Increase Neo-Angiogenesis and Albumin Production in a Liver Tissue-Engineered Engraftment.

Authors:  Amedeo Carraro; Maurizio Buggio; Chiara Gardin; Umberto Tedeschi; Letizia Ferroni; Padova-Barbara Zavan
Journal:  Int J Mol Sci       Date:  2016-03-12       Impact factor: 5.923

Review 5.  3D Bone Biomimetic Scaffolds for Basic and Translational Studies with Mesenchymal Stem Cells.

Authors:  Cristina Sobacchi; Marco Erreni; Dario Strina; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Int J Mol Sci       Date:  2018-10-13       Impact factor: 5.923

6.  Intra-cerebral implantation of a variety of collagenous scaffolds with nervous embryonic cells.

Authors:  Jacek Drobnik; Krystyna Pietrucha; Karolina Janczar; Lech Polis; Bartosz Polis; Marta Safandowska; Jacek Szymański
Journal:  Exp Ther Med       Date:  2019-10-21       Impact factor: 2.447

Review 7.  Collagen Scaffolds in Cartilage Tissue Engineering and Relevant Approaches for Future Development.

Authors:  Vincent Irawan; Tzu-Cheng Sung; Akon Higuchi; Toshiyuki Ikoma
Journal:  Tissue Eng Regen Med       Date:  2018-07-25       Impact factor: 4.169

8.  Prussian Blue Nanoparticle-Labeled Mesenchymal Stem Cells: Evaluation of Cell Viability, Proliferation, Migration, Differentiation, Cytoskeleton, and Protein Expression In Vitro.

Authors:  Jirui Wen; Zhiwei Zhao; Ruijie Tong; Liwei Huang; Yali Miao; Jiang Wu
Journal:  Nanoscale Res Lett       Date:  2018-10-22       Impact factor: 4.703

9.  Effect of Nanostructured Scaffold on Human Adipose-Derived Stem Cells: Outcome of In Vitro Experiments.

Authors:  Marina Borgese; Ludovica Barone; Federica Rossi; Mario Raspanti; Roberto Papait; Luigi Valdatta; Giovanni Bernardini; Rosalba Gornati
Journal:  Nanomaterials (Basel)       Date:  2020-09-12       Impact factor: 5.076

Review 10.  Trends in Articular Cartilage Tissue Engineering: 3D Mesenchymal Stem Cell Sheets as Candidates for Engineered Hyaline-Like Cartilage.

Authors:  Hallie Thorp; Kyungsook Kim; Makoto Kondo; Travis Maak; David W Grainger; Teruo Okano
Journal:  Cells       Date:  2021-03-13       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.